FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016752064> ?p ?o ?g. }

• W2016752064 endingPage "1924" @default.
• W2016752064 startingPage "1913" @default.
• W2016752064 abstract "3- And 4-imidazol-1-yl-methyl substituted biphenyl compounds (named as meta- and para-substituted compounds) were synthesized bearing additional substituents in 3'-/4'-position as inhibitors of P450 17 (17alpha-hydroxylase-C17,20-lyase). P450 17 is the key enzyme of androgen biosynthesis. Its inhibition is a novel therapeutic strategy for treatment of prostate cancer (PC). Twenty-nine compounds were synthesized by Ar-Mg-Br, Negishi or Suzuki aryl-aryl cross coupling and tested toward human and rat enzyme. Most of the compounds showed moderate to excellent activity against one of the enzymes (0.087 microM < or = IC50 < or = 7.7 microM (ketoconazole: 0.74 microM) for the human enzyme, 0.63 microM < or = IC50 < or = 32 microM (ketoconazole: 67 microM) for the rat enzyme). Interestingly, strong species differences were observed. In addition compounds were tested for inhibition toward P450 arom. The 3-imidazol-1-yl-methyl substituted compounds showed good inhibitory activity of P450 arom, while for the 4-substituted compounds negligible inhibition was found. For the most active group of P450 17 inhibitors, (i.e. the 4-imidazol-1-yl-methyl substituted compounds) a QSAR study was performed for inhibition of the human enzyme leading to the result that a hydrophilic substituent in 3'-/4'-position is very important. The most promising compounds (with respect to activity toward both enzymes) were tested in vivo using SD-rats for reduction of plasma testosterone concentrations 2 and 6 h after single i.p. application. The fluorine substituted compound 8c decreased the testosterone plasma concentration to castration level (after 2 h; 5 mg/kg) showing a biological half live of about 6 h." @default.
• W2016752064 created "2016-06-24" @default.
• W2016752064 creator A5015608341 @default.
• W2016752064 creator A5038528728 @default.
• W2016752064 creator A5040011369 @default.
• W2016752064 creator A5077659447 @default.
• W2016752064 date "1999-09-01" @default.
• W2016752064 modified "2023-10-17" @default.
• W2016752064 title "Imidazole substituted biphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer" @default.
• W2016752064 cites W1968421454 @default.
• W2016752064 cites W1979276942 @default.
• W2016752064 cites W1982298201 @default.
• W2016752064 cites W1993808852 @default.
• W2016752064 cites W1998902423 @default.
• W2016752064 cites W2000824159 @default.
• W2016752064 cites W2004734169 @default.
• W2016752064 cites W2009936700 @default.
• W2016752064 cites W2022450540 @default.
• W2016752064 cites W2023429264 @default.
• W2016752064 cites W2027081726 @default.
• W2016752064 cites W2031082832 @default.
• W2016752064 cites W2032112177 @default.
• W2016752064 cites W2034262530 @default.
• W2016752064 cites W2043096764 @default.
• W2016752064 cites W2051169106 @default.
• W2016752064 cites W2064882641 @default.
• W2016752064 cites W2071699307 @default.
• W2016752064 cites W2078049075 @default.
• W2016752064 cites W2083307050 @default.
• W2016752064 cites W2085581871 @default.
• W2016752064 cites W2129067715 @default.
• W2016752064 cites W2766040292 @default.
• W2016752064 cites W2949266711 @default.
• W2016752064 cites W2949719754 @default.
• W2016752064 cites W2951613918 @default.
• W2016752064 cites W2952391513 @default.
• W2016752064 cites W2953094172 @default.
• W2016752064 cites W4240237883 @default.
• W2016752064 doi "https://doi.org/10.1016/s0968-0896(99)00160-1" @default.
• W2016752064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10530940" @default.
• W2016752064 hasPublicationYear "1999" @default.
• W2016752064 type Work @default.
• W2016752064 sameAs 2016752064 @default.
• W2016752064 citedByCount "56" @default.
• W2016752064 countsByYear W20167520642014 @default.
• W2016752064 countsByYear W20167520642016 @default.
• W2016752064 countsByYear W20167520642017 @default.
• W2016752064 countsByYear W20167520642020 @default.
• W2016752064 countsByYear W20167520642023 @default.
• W2016752064 crossrefType "journal-article" @default.
• W2016752064 hasAuthorship W2016752064A5015608341 @default.
• W2016752064 hasAuthorship W2016752064A5038528728 @default.
• W2016752064 hasAuthorship W2016752064A5040011369 @default.
• W2016752064 hasAuthorship W2016752064A5077659447 @default.
• W2016752064 hasConcept C114373084 @default.
• W2016752064 hasConcept C150903083 @default.
• W2016752064 hasConcept C16005928 @default.
• W2016752064 hasConcept C181199279 @default.
• W2016752064 hasConcept C185592680 @default.
• W2016752064 hasConcept C202751555 @default.
• W2016752064 hasConcept C207001950 @default.
• W2016752064 hasConcept C2776980637 @default.
• W2016752064 hasConcept C2778689049 @default.
• W2016752064 hasConcept C2779548794 @default.
• W2016752064 hasConcept C2781064554 @default.
• W2016752064 hasConcept C55493867 @default.
• W2016752064 hasConcept C71240020 @default.
• W2016752064 hasConcept C71924100 @default.
• W2016752064 hasConcept C86803240 @default.
• W2016752064 hasConceptScore W2016752064C114373084 @default.
• W2016752064 hasConceptScore W2016752064C150903083 @default.
• W2016752064 hasConceptScore W2016752064C16005928 @default.
• W2016752064 hasConceptScore W2016752064C181199279 @default.
• W2016752064 hasConceptScore W2016752064C185592680 @default.
• W2016752064 hasConceptScore W2016752064C202751555 @default.
• W2016752064 hasConceptScore W2016752064C207001950 @default.
• W2016752064 hasConceptScore W2016752064C2776980637 @default.
• W2016752064 hasConceptScore W2016752064C2778689049 @default.
• W2016752064 hasConceptScore W2016752064C2779548794 @default.
• W2016752064 hasConceptScore W2016752064C2781064554 @default.
• W2016752064 hasConceptScore W2016752064C55493867 @default.
• W2016752064 hasConceptScore W2016752064C71240020 @default.
• W2016752064 hasConceptScore W2016752064C71924100 @default.
• W2016752064 hasConceptScore W2016752064C86803240 @default.
• W2016752064 hasIssue "9" @default.
• W2016752064 hasLocation W20167520641 @default.
• W2016752064 hasLocation W20167520642 @default.
• W2016752064 hasOpenAccess W2016752064 @default.
• W2016752064 hasPrimaryLocation W20167520641 @default.
• W2016752064 hasRelatedWork W2020980248 @default.
• W2016752064 hasRelatedWork W2021298759 @default.
• W2016752064 hasRelatedWork W2037188214 @default.
• W2016752064 hasRelatedWork W2039340360 @default.
• W2016752064 hasRelatedWork W2146767040 @default.
• W2016752064 hasRelatedWork W2173495551 @default.
• W2016752064 hasRelatedWork W2413510533 @default.
• W2016752064 hasRelatedWork W2527163109 @default.
• W2016752064 hasRelatedWork W2952849161 @default.

• next